다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NBIX) 뉴스

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/24	06:05	PR Newswire (US)	Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/22	06:05	PR Newswire (US)	Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/18	06:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/16	06:19	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/08	22:30	PR Newswire (US)	Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/07	06:01	PR Newswire (US)	Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/04	06:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/01	06:17	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	22:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	22:00	PR Newswire (US)	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	06:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	06:37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/18	06:29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/14	08:55	PR Newswire (US)	Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/04	08:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/30	03:41	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/27	06:01	PR Newswire (US)	Neurocrine Biosciences to Participate at Investor Conferences in December	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/13	07:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/08	09:42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/07	22:30	PR Newswire (US)	Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/06	06:01	PR Newswire (US)	Neurocrine Biosciences to Participate at Investor Conferences in November	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/04	22:30	PR Newswire (US)	Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/04	22:25	PR Newswire (US)	Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/02	08:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/01	21:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/30	20:04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/30	20:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/30	20:00	PR Newswire (US)	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/12	05:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/10	05:01	PR Newswire (US)	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results	NASDAQ:NBIX	Neurocrine Biosciences Inc

검색 관련기사 보기:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 다음 >>

iShares Euro Dividend UC...

D Amico International Sh...

Vontobel Financial Produ...

Invesco Global High Yiel...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관